StreetInsider.com News Articles

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Tue, 10 Feb 2026 08:00:00 -0500

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT

─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.

Titled ‘Inside

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Tue, 10 Feb 2026 08:00:00 -0500

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT
─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.
Titled ‘Inside

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Tue, 10 Feb 2026 08:00:00 -0500

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT
─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.
Titled ‘Inside

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Tue, 10 Feb 2026 08:00:00 -0500

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT
─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.
Titled ‘Inside

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Tue, 10 Feb 2026 08:00:00 -0500

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT
─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.
Titled ‘Inside

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Tue, 10 Feb 2026 08:00:00 -0500

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT
─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.
Titled ‘Inside

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Tue, 10 Feb 2026 08:00:00 -0500

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT
─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.
Titled ‘Inside

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Tue, 10 Feb 2026 08:00:00 -0500

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT
─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.
Titled ‘Inside

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Tue, 10 Feb 2026 08:00:00 -0500

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT
─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.
Titled ‘Inside

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Tue, 10 Feb 2026 08:00:00 -0500

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT
─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.
Titled ‘Inside

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Tue, 10 Feb 2026 08:00:00 -0500

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT
─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.
Titled ‘Inside

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

Tue, 10 Feb 2026 08:00:00 -0500

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT
─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians specializing in neurological disorders

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.
Titled ‘Inside

H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)

Mon, 02 Feb 2026 06:50:57 -0500

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $18.00 price target on Coya Therapeutics (NASDAQ: COYA).
The analyst commented: "On January 29, 2026, Coya Therapeutics entered into a securities purchase agreement (SPA) with certain accredited investors for the issuance and sale in a private placement of 2,522,727 shares of the company’s common stock, par value $0.0001 per share, at a purchase price of $4.40 per share. This equity offering is expected to result in gross proceeds to the company of approximately $11.1M, before deducting offering expenses payable by Coya. No broker, placement agent or investment banker was engaged in

Form SCHEDULE 13G/A Coya Therapeutics, Inc. Filed by: VANGUARD GROUP INC

Fri, 30 Jan 2026 13:28:00 -0500
si-local-file:///var/storage/secattach/20260130/25922080.html

Form SCHEDULE 13G/A Coya Therapeutics, Inc. Filed by: VANGUARD GROUP INC

Fri, 30 Jan 2026 13:28:00 -0500
si-local-file:///var/storage/secattach/20260130/25922080.html

Form 8-K Coya Therapeutics, Inc. For: Jan 29

Fri, 30 Jan 2026 08:07:00 -0500
si-local-file:///var/storage/secattach/20260130/25919995.html

Form 8-K Coya Therapeutics, Inc. For: Jan 29

Fri, 30 Jan 2026 08:07:00 -0500
si-local-file:///var/storage/secattach/20260130/25919995.html

Coya Therapeutics raises $11.1 million in private placement

Fri, 30 Jan 2026 08:00:18 -0500

Coya Therapeutics Inc. (NASDAQ: COYA) announced it has entered into a securities purchase agreement for a $11.1 million private placement. The biotechnology company will sell 2,522,727 shares of common stock at $4.40 per share.

Dr. Reddy's Laboratories Inc., a subsidiary of Coya's strategic collaborator, invested $10 million in the offering. Greenlight Capital, described as the company's largest institutional shareholder, contributed $1.1 million.

The transaction is expected to close on or about January 30, 2026, subject to customary closing conditions. No broker, placement agent or investment banker was engaged in the transaction.

Coya stated it intends to use the net proceeds to accelerate technology

Coya Therapeutics raises $11.1 million in private placement

Fri, 30 Jan 2026 08:00:18 -0500

Coya Therapeutics Inc. (NASDAQ: COYA) announced it has entered into a securities purchase agreement for a $11.1 million private placement. The biotechnology company will sell 2,522,727 shares of common stock at $4.40 per share.

Dr. Reddy's Laboratories Inc., a subsidiary of Coya's strategic collaborator, invested $10 million in the offering. Greenlight Capital, described as the company's largest institutional shareholder, contributed $1.1 million.

The transaction is expected to close on or about January 30, 2026, subject to customary closing conditions. No broker, placement agent or investment banker was engaged in the transaction.

Coya stated it intends to use the net proceeds to accelerate technology

Coya Therapeutics raises $11.1 million in private placement

Fri, 30 Jan 2026 08:00:18 -0500

Coya Therapeutics Inc. (NASDAQ: COYA) announced it has entered into a securities purchase agreement for a $11.1 million private placement. The biotechnology company will sell 2,522,727 shares of common stock at $4.40 per share.

Dr. Reddy's Laboratories Inc., a subsidiary of Coya's strategic collaborator, invested $10 million in the offering. Greenlight Capital, described as the company's largest institutional shareholder, contributed $1.1 million.

The transaction is expected to close on or about January 30, 2026, subject to customary closing conditions. No broker, placement agent or investment banker was engaged in the transaction.

Coya stated it intends to use the net proceeds to accelerate technology

Coya Therapeutics raises $11.1 million in private placement

Fri, 30 Jan 2026 08:00:18 -0500

Coya Therapeutics Inc. (NASDAQ: COYA) announced it has entered into a securities purchase agreement for a $11.1 million private placement. The biotechnology company will sell 2,522,727 shares of common stock at $4.40 per share.

Dr. Reddy's Laboratories Inc., a subsidiary of Coya's strategic collaborator, invested $10 million in the offering. Greenlight Capital, described as the company's largest institutional shareholder, contributed $1.1 million.

The transaction is expected to close on or about January 30, 2026, subject to customary closing conditions. No broker, placement agent or investment banker was engaged in the transaction.

Coya stated it intends to use the net proceeds to accelerate technology

Coya Therapeutics raises $11.1 million in private placement

Fri, 30 Jan 2026 08:00:18 -0500

Coya Therapeutics Inc. (NASDAQ: COYA) announced it has entered into a securities purchase agreement for a $11.1 million private placement. The biotechnology company will sell 2,522,727 shares of common stock at $4.40 per share.

Dr. Reddy's Laboratories Inc., a subsidiary of Coya's strategic collaborator, invested $10 million in the offering. Greenlight Capital, described as the company's largest institutional shareholder, contributed $1.1 million.

The transaction is expected to close on or about January 30, 2026, subject to customary closing conditions. No broker, placement agent or investment banker was engaged in the transaction.

Coya stated it intends to use the net proceeds to accelerate technology

Coya Therapeutics raises $11.1 million in private placement

Fri, 30 Jan 2026 08:00:18 -0500

Coya Therapeutics Inc. (NASDAQ: COYA) announced it has entered into a securities purchase agreement for a $11.1 million private placement. The biotechnology company will sell 2,522,727 shares of common stock at $4.40 per share.

Dr. Reddy's Laboratories Inc., a subsidiary of Coya's strategic collaborator, invested $10 million in the offering. Greenlight Capital, described as the company's largest institutional shareholder, contributed $1.1 million.

The transaction is expected to close on or about January 30, 2026, subject to customary closing conditions. No broker, placement agent or investment banker was engaged in the transaction.

Coya stated it intends to use the net proceeds to accelerate technology

Coya Therapeutics Announces $11.1 Million Private Placement

Fri, 30 Jan 2026 08:00:00 -0500

- Dr. Reddy’s Laboratories, Inc., a subsidiary of Coya’s current strategic collaborator, makes a $10 million investment

- Greenlight Capital, Coya’s largest institutional shareholder, is the only other investor participating in the offering

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price

Coya Therapeutics Announces $11.1 Million Private Placement

Fri, 30 Jan 2026 08:00:00 -0500

- Dr. Reddy’s Laboratories, Inc., a subsidiary of Coya’s current strategic collaborator, makes a $10 million investment

- Greenlight Capital, Coya’s largest institutional shareholder, is the only other investor participating in the offering

HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price